152 related articles for article (PubMed ID: 3291282)
1. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F
Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
[No Abstract] [Full Text] [Related]
2. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
Truog AW; Wozniak SP
Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
[TBL] [Abstract][Full Text] [Related]
3. Prevention of graft versus host disease following allogeneic bone marrow transplantation.
Powles RL; Goss GD; Millar J; Maitland J; Borthwick-Clark C; Al-Jundi A
Tokai J Exp Clin Med; 1985 Jun; 10(2-3):133-8. PubMed ID: 3914738
[No Abstract] [Full Text] [Related]
4. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
[No Abstract] [Full Text] [Related]
5. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate.
Tollemar J; Ringdén O; Sundberg B; Bolme P; Brattström C; Gahrton G; Johansen L; Lönnqvist B
Transplant Proc; 1988 Jun; 20(3):494-8. PubMed ID: 3381257
[No Abstract] [Full Text] [Related]
6. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Kastelan A; Marusić M; Zupancić-Salek S
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
[No Abstract] [Full Text] [Related]
7. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
[No Abstract] [Full Text] [Related]
8. Cyclosporine administration practices on bone marrow transplant units: a national survey.
Caudell KA; Adams J
Oncol Nurs Forum; 1990; 17(4):563-8. PubMed ID: 2119035
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
Forman SJ; Blume KG; Krance RA; Miner PJ; Metter GE; Hill LR; O'Donnell MR; Nademanee AP; Snyder DS
Transplant Proc; 1987 Feb; 19(1 Pt 3):2605-7. PubMed ID: 3079090
[No Abstract] [Full Text] [Related]
12. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
[No Abstract] [Full Text] [Related]
13. Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT).
Blaise D; Guyotat D; Reiffers J; Olive D; Michallet M; Bellanger C; Vernant JP; Ifrah N; Attal M; Vilmer E
Bone Marrow Transplant; 1991; 7 Suppl 2():150. PubMed ID: 1878689
[No Abstract] [Full Text] [Related]
14. [Cyclosporine in allogeneic bone marrow transplantation in children].
Kojima S; Fukuda M; Horibe K; Matsuyama K
Rinsho Ketsueki; 1987 Sep; 28(9):1576-82. PubMed ID: 3325658
[No Abstract] [Full Text] [Related]
15. Combination prophylactic immunosuppression in bone marrow transplantation.
Szer J
Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
[No Abstract] [Full Text] [Related]
16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
17. Results of four different protocols for prophylaxis against graft-versus-host disease.
Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
[No Abstract] [Full Text] [Related]
18. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
Ruutu T; Volin L; Elonen E
Transplant Proc; 1988 Jun; 20(3):491-3. PubMed ID: 3289191
[No Abstract] [Full Text] [Related]
19. Cyclosporin A: use in preventing graft versus host disease.
Klemm P
Oncol Nurs Forum; 1985; 12(5):25-32. PubMed ID: 3898028
[No Abstract] [Full Text] [Related]
20. Syngeneic graft-versus-host disease after allogeneic bone marrow transplantation and cyclosporine treatment.
Hess AD; Vogelsang GB; Silanskis M; Friedman KA; Beschorner WE; Santos GW
Transplant Proc; 1988 Jun; 20(3 Suppl 3):487-92. PubMed ID: 3291285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
